IX Biopharma Advances Wafermine Out-Licensing, Starts Preclinical Trials for IXB 401

MT NewswiresSep 17 10:41

New Study Demonstrates That SL-NAD+ Delivers NAD+ Into Cells

PR NewswireSep 2 09:00

IX Biopharma's New Wafer Revolutionizes NAD+ Supplementation

TipRanksSep 2 08:17

IX Biopharma Widens Net Loss by 12% in FY2024

Singapore Business ReviewAug 27 16:51

IX Biopharma's Net Attributable Loss Widens in Fiscal H2

MT NewswiresAug 26 12:46

IX Biopharma Full Year 2024 Earnings: S$0.014 Loss per Share (Vs S$0.013 Loss in FY 2023)

Yahoo FinanceAug 25 09:57